Advertisement

Depth of response of induction therapy and consecutive maintenance treatment in patients with RAS wild-type metastatic colorectal cancer: An analysis of the PanaMa trial (AIO KRK 0212)

Published:November 15, 2022DOI:https://doi.org/10.1016/j.ejca.2022.09.011

      Highlights

      • In the PanaMa trial, the median overall DpR was 58.1% versus 54.9%, respectively.
      • Approximately 75% of the overall DpR was achieved during induction therapy.
      • Additional DpR achieved by maintenance therapy was numerically greater with Pmab.
      • DpR to induction was prognostic for PFS and OS of maintenance therapy.

      Abstract

      Background

      In patients with RAS wild-type metastatic colorectal cancer, depth of response (DpR) has gained importance as a novel end-point in clinical trials. We investigated the overall DpR, as well as the prognostic and predictive impact of DpR to induction therapy (six cycles of 5-fluorouracil, leucovorin [FU/FA], oxaliplatin [FOLFOX] and panitumumab [Pmab]) on consecutive maintenance therapy (FU/FA plus Pmab or FU/FA alone) in patients treated within the PanaMa trial.

      Methods

      Central radiological assessment was performed according to RECIST 1.1. DpR was defined as percentage change in tumour diameter within defined time intervals (induction therapy, maintenance therapy, total course of therapy). For prognostic and predictive analyses, median DpR (</≥) served as threshold.

      Results

      Out of 248 patients receiving maintenance therapy, 211 were evaluable for DpR analyses (FU/FA + Pmab, n = 106; FU/FA alone, n = 105). The overall DpR in all patients was 56.5%. DpR of induction therapy (42.5%) accounted for the largest proportion (75.2%) of the overall DpR. While greater DpR to induction therapy was significantly associated with prolonged PFS (HR 0.70, 95% CI 0.52–0.93, p = 0.013) and OS (HR 0.38, 95% CI 0.28–0.51, p < 0.001), there was no significant correlation of DpR and maintenance treatment arm.

      Conclusions

      In the PanaMa trial, the overall DpR was similar to DpR achieved by other epidermal growth factor receptor-based regimens. DpR to induction therapy accounted for three quarters of the total tumour shrinkage potentially suggesting that FOLFOX plus Pmab can be de-escalated following induction without substantially compromising efficacy. DpR to induction therapy was prognostic but not predictive for efficacy of consecutive maintenance therapy.

      Clinical trial information

      NCT01991873.

      Graphical abstract

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Arnold D.
        • Lueza B.
        • Douillard J.Y.
        • et al.
        Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
        Ann Oncol. 2017; 28: 1713-1729
        • Douillard J.Y.
        • Oliner K.S.
        • Siena S.
        • et al.
        Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
        N Engl J Med. 2013; 369: 1023-1034
        • Heinemann V.
        • von Weikersthal L.F.
        • Decker T.
        • et al.
        FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
        Lancet Oncol. 2014; 15: 1065-1075
        • Holch J.W.
        • Ricard I.
        • Stintzing S.
        • Modest D.P.
        • Heinemann V.
        The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials.
        Eur J Cancer. 2017; 70: 87-98
        • Schwartzberg L.S.
        • Rivera F.
        • Karthaus M.
        • et al.
        PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS Exon 2 metastatic colorectal cancer.
        J Clin Oncol. 2014 Jul 20;32(21):2240-7. 2014;
        • Van Cutsem E.
        • Cervantes A.
        • Adam R.
        • et al.
        ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.
        Ann Oncol. 2016; 27: 1386-1422
        • Van Cutsem E.
        • Lenz H.J.
        • Kohne C.H.
        • et al.
        Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
        J Clin Oncol. 2015; 33: 692-700
        • Venook A.P.
        • Niedzwiecki D.
        • Lenz H.J.
        • et al.
        Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type Advanced or metastatic colorectal cancer: a randomized clinical trial.
        JAMA. 2017; 317: 2392-2401
        • Modest D.P.
        • Laubender R.P.
        • Stintzing S.
        • et al.
        Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial.
        Acta Oncol. 2013; 52: 956-962
        • Piessevaux H.
        • Buyse M.
        • Schlichting M.
        • et al.
        Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.
        J Clin Oncol. 2013; 31: 3764-3775
        • Stintzing S.
        • Modest D.P.
        • Rossius L.
        • et al.
        FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
        Lancet Oncol. 2016; 17: 1426-1434
        • Taieb J.
        • Rivera F.
        • Siena S.
        • et al.
        Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials.
        J Cancer Res Clin Oncol. 2018; 144: 321-335
        • Heinemann V.
        • Stintzing S.
        • Modest D.P.
        • Giessen-Jung C.
        • Michl M.
        • Mansmann U.R.
        Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC).
        Eur J Cancer. 2015; 51: 1927-1936
        • Stintzing S.
        • Modest D.P.
        • Rossius L.
        • et al.
        FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial.
        Lancet Oncol. 2016; 17: 1426-1434
        • Modest D.P.
        • Martens U.M.
        • Riera-Knorrenschild J.
        • et al.
        FOLFOXIRI plus panitumumab as first-line treatment of RAS wild-type metastatic colorectal cancer: the randomized, open-label, phase II VOLFI study (AIO KRK0109).
        J Clin Oncol. 2019; 37: 3401-3411
        • Cremolini C.
        • Loupakis F.
        • Antoniotti C.
        • et al.
        Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest.
        Ann Oncol. 2015; 26: 1188-1194
        • Kurreck A.
        • Heinemann V.
        • Fischer von Weikersthal L.
        • et al.
        Response and disease dynamics in untreated metastatic colorectal cancer with bevacizumab-based sequential vs. Combination chemotherapy-analysis of the phase 3 XELAVIRI trial.
        Front Oncol. 2022; 12751453
        • Kurreck A.
        • Geissler M.
        • Martens U.M.
        • et al.
        Dynamics in treatment response and disease progression of metastatic colorectal cancer (mCRC) patients with focus on BRAF status and primary tumor location: analysis of untreated RAS-wild-type mCRC patients receiving FOLFOXIRI either with or without panitumumab in the VOLFI trial (AIO KRK0109).
        J Cancer Res Clin Oncol. 2020; 146: 2681-2691
        • Modest D.P.
        • Karthaus M.
        • Fruehauf S.
        • et al.
        Panitumumab plus fluorouracil and folinic acid versus fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer: the randomized PanaMa trial (AIO KRK 0212).
        J Clin Oncol. 2022; 40: 72-82
        • Mansmann U.R.
        • Sartorius U.
        • Laubender R.P.
        • Giessen C.A.
        • Esser R.
        • Heinemann V.
        Deepness of response: a quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC.
        J Clin Oncol. 2013; 31: 427
        • Peeters M.
        • Price T.
        • Taieb J.
        • et al.
        Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials.
        Br J Cancer. 2018; 119: 303-312
        • Froelich M.F.
        • Petersen E.L.
        • Heinemann V.
        • et al.
        Impact of size and location of metastases on early tumor shrinkage and depth of response in patients with metastatic colorectal cancer: subgroup findings of the randomized, open-label phase 3 trial FIRE-3/AIO KRK-0306.
        Clin Colorectal Cancer. 2020; 19 (e5): 291-300
        • Franko J.
        • Shi Q.
        • Meyers J.P.
        • et al.
        Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
        Lancet Oncol. 2016; 17: 1709-1719
        • Manca P.
        • Corallo S.
        • Randon G.
        • et al.
        Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer.
        Eur J Cancer. 2021; 144: 31-40